Search Results

You are looking at 1 - 10 of 170 items for :

  • "non-Hodgkin's lymphoma" x
Clear All
Full access

Andrew D. Zelenetz, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, Naresh Bellam, John C. Byrd, Myron S. Czuczman, Luis E. Fayad, Martha J. Glenn, Jon P. Gockerman, Leo I. Gordon, Nancy Lee Harris, Richard T. Hoppe, Steven M. Horwitz, Christopher R. Kelsey, Youn H. Kim, Ann S. LaCasce, Auayporn Nademanee, Pierluigi Porcu, Oliver Press, Barbara Pro, Nashitha Reddy, Lubomir Sokol, Lode J. Swinnen, Christina Tsien, Julie M. Vose, William G. Wierda, Joachim Yahalom and Nadeem Zafar

NCCN Clinical Practice Guidelines in Oncology for Non-Hodgkin's Lymphomas NCCN Categories of Evidence and Consensus Category 1: The recommendation is based on high-level evidence (e.g., randomized controlled trials) and there is uniform

Full access

Steven M. Horwitz, Andrew D. Zelenetz, Leo I. Gordon, William G. Wierda, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, John C. Byrd, Luis E. Fayad, Richard I. Fisher, Martha J. Glenn, Thomas M. Habermann, Nancy Lee Harris, Francisco Hernandez-Ilizaliturri, Richard T. Hoppe, Mark S. Kaminski, Christopher R. Kelsey, Youn H. Kim, Susan Krivacic, Ann S. LaCasce, Matthew Lunning, Auayporn Nademanee, Oliver Press, Rachel Rabinovitch, Nishitha Reddy, Erin Reid, Kenneth Roberts, Ayman A. Saad, Lubomir Sokol, Lode J. Swinnen, Julie M. Vose, Joachim Yahalom, Nadeem Zafar, Mary Dwyer, Hema Sundar and Pierluigi Porcu

this activity, participants will be able to: Integrate into professional practice the updates to NCCN Guidelines for Non-Hodgkin's Lymphomas Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Non-Hodgkin

Full access

Mauro P. Avanzi and Renier J. Brentjens

-cell acute lymphoblastic leukemia (B-ALL) and non-Hodgkin's lymphoma (NHL). 1 – 4 Although clinical experience with CAR-Ts is more abundant in ALL, the benefits are being observed in other hematologic malignancies, such as NHL, chronic lymphocytic leukemia

Full access

Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center

Non-Hodgkin's lymphomas (NHL) are a heterogeneous group of lymphoproliferative disorders originating in B-lymphocytes, T-lymphocytes, or natural killer (NK) lymphocytes. An estimated 63,190 new cases of NHL, including 34,200 in men and 28,990 in women, will be diagnosed in 2007, and 18,660 deaths will occur. NHL is the fifth leading type of new cancer diagnosed and the ninth leading cause of cancer deaths among men and the seventh among women. The median age of individuals with NHL has risen in the past 2 decades, resulting in a patient population that may also have significant comorbid conditions, complicating treatment options. Important updates to these guidelines for 2008 include expanded second-line therapy options for patients with diffuse large B-cell lymphoma and those with peripheral T-cell lymphomas. In addition, the mycosis fungoides/Sézary syndrome section now includes pages on updated staging and classification systems and suggested treatment regimens.

For the most recent version of the guidelines, please visit NCCN.org

Full access

Andrew D. Zelenetz, Leo I. Gordon, William G. Wierda, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, John C. Byrd, Luis E. Fayad, Richard I. Fisher, Martha J. Glenn, Thomas M. Habermann, Nancy Lee Harris, Francisco Hernandez-Ilizaliturri, Richard T. Hoppe, Steven M. Horwitz, Mark S. Kaminski, Christopher R. Kelsey, Youn H. Kim, Susan Krivacic, Ann S. LaCasce, Matthew Lunning, Auayporn Nademanee, Pierluigi Porcu, Oliver Press, Rachel Rabinovitch, Nishitha Reddy, Erin Reid, Kenneth Roberts, Ayman A. Saad, Lubomir Sokol, Lode J. Swinnen, Julie M. Vose, Joachim Yahalom, Nadeem Zafar, Mary Dwyer and Hema Sundar

Diffuse large B-cell lymphomas (DLBCL) are the most common lymphoid neoplasms in adults, accounting for approximately 32.5% of non-Hodgkin's lymphoma (NHL) cases diagnosed annually. 1 Gene expression profiling (GEP) has revealed significant heterogeneity

Full access

Memorial Sloan-Kettering Cancer Center

Non-Hodgkin's lymphomas (NHLs) may be classified on the basis of morphology, natural history, and immunophenotypic and molecular characteristics. These guidelines were developed for more common NHL histologic types, including chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, and diffuse large B-cell lymphoma, and for less common entities with unique natural histories and therapies, such as marginal zone lymphoma, mantle cell lymphoma, and highly aggressive lymphoma subtypes, including Burkitt's, and lymphoblastic lymphomas and AIDS-related B-cell lymphomas. Certain components of the diagnosis and therapy of the various NHLs are similar. In all cases, an accurate pathologic diagnosis must first be made.

For the most recent version of the guidelines, please visit NCCN.org

Full access

An estimated 54,370 new cases of non-Hodgkin's lymphoma (NHL) will be diagnosed in 2004, and 19,410 individuals with NHL will die this year. NHL is the sixth leading site of new cancer cases among men and women, accounting for 4% of new cancer cases. NHL is also one of the few malignancies rising in incidence. The NHLs may be classified on the basis of morphology, natural history, and immunophenotypic and molecular characteristics. The National Comprehensive Cancer Network (NCCN) guidelines were developed for more common NHL histologic types and for less common entities with unique natural histories and therapies. This version of the guidelines incorporates the most significant changes to the guidelines since the initial publication.

For the most recent version of the guidelines, please visit NCCN.org

Full access

Ali Bazarbachi, Hamdy A. Azim, Hussain Alizadeh, Mahmoud Aljurf, Ibrahim Barista, Naeem A. Chaudhri, Zahira Fahed, Omar A. Fahmy, Ardeshir Ghavamzadeh, Mohamed H. Khalaf, Sami Khatib, Aghiad Kutoubi, Semra Paydas, Hanadi Rafii Elayoubi, Ghazi Zaatari, Hamdy M. Zawam and Andrew D. Zelenetz

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) on Non-Hodgkin's Lymphoma and the 2008 version of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) on Hodgkin Lymphoma (to view the most recent version of these

Full access

Mathias Rummel

Epidemiology Non-Hodgkin's lymphoma (NHL) represents a diverse group of hematologic malignancies originating in B or T lymphocytes. Approximately 85% of NHLs are of B-cell origin, with the remainder mostly of T-cell origin. 1 The most common NHL

Full access

Jerald P. Radich, Andrew D. Zelenetz, Wing C. Chan, Carlo M. Croce, Myron S. Czuczman, Harry P. Erba, Sandra J. Horning, Jane Houldsworth, B. Douglas Smith, David S. Snyder, Hema M. Sundar, Meir Wetzler and Jane N. Winter

. Recurrent chromosomal translocations and fusion genes in leukemia-lymphoma cell lines . Leukemia 1995 ; 9 : 480 – 500 . 3 Vega F Medeiros LJ . Chromosomal translocations involved in non-Hodgkin lymphomas . Arch Pathol Lab Med 2003 ; 127